on The Vanguard Group, Inc. (isin : US12572Q1058)
The Vanguard Group Reports Stake in Avadel Pharmaceuticals
The Vanguard Group, Inc. has disclosed its interests in Avadel Pharmaceuticals plc under Form 8.3, as per the Irish Takeover Panel regulations. As of January 5, 2026, Vanguard holds 5,862,436 US$0.01 ordinary shares, representing 6.02% of the company's relevant securities.
No cash-settled or stock-settled derivatives, nor any agreements to purchase or sell additional shares, have been reported. However, Vanguard recently purchased 948 of these shares at a rate of 21.50 USD per unit.
The disclosure indicates that no indemnity, option, or other arrangements exist involving the disclosed securities. Moreover, there are no agreements relating to the voting rights or future acquisition/disposal connected to any derivative.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all The Vanguard Group, Inc. news